Volume 4 Number 3
Website Exclusive Contents!
Editorial
EAPCI column
55
"Embargo" on scientific news, a late breaking message from the Ministry of Truth (MiniTrue)EuroInterv.2008;4:307-308
Focus article
56
Interventional cardiology highlights of the European Society of Cardiology congress, 2008EuroInterv.2008;4:309-310
Clinical research
57
Four-year safety and efficacy of the unrestricted use of sirolimus- and paclitaxel-eluting stents in coronary artery bypass graftsEuroInterv.2008;4:311-317
58
Characterisation of the "vulnerable" coronary plaque by multi-detector computed tomography: a correlative study with intravascular ultrasound-derived radiofrequency analysis of plaque compositionEuroInterv.2008;4:318-323
59
Very late thrombosis in acute myocardial infarction: drug-eluting versus uncoated stentsEuroInterv.2008;4:324-330
60
The TandemHeart®, percutaneous transseptal left ventricular assist device: a safeguard in high-risk percutaneous coronary interventions. The six-year Rotterdam experienceEuroInterv.2008;4:331-337
61
Long-term safety and efficacy are observed after implantation of Zotarolimus-Eluting Stent in real-world clinical practiceEuroInterv.2008;4:338-344
62
"Gender paradox" in outcome after percutaneous coronary intervention with paclitaxel eluting stentsEuroInterv.2008;4:345-350
63
Early echocardiographic evaluation following percutaneous implantation with the self-expanding CoreValve ReValving System aortic valve bioprosthesisEuroInterv.2008;4:351-357
64
The "mini-crush technique" for the treatment of coronary trifurcation lesionsEuroInterv.2008;4:358-364
65
Comparison of primary angioplasty in rural and metropolitan areas within an integrated networkEuroInterv.2008;4:365-372
66
Relationship between coronary and renal artery disease and associated risk factors in hypertensive and diabetic patients undergoing coronary angiographyEuroInterv.2008;4:373-377
Expert review
67
A primer on the immune system in the pathogenesis and treatment of atherosclerosisEuroInterv.2008;4:378-390
Experimental research
68
Comparison of drug-eluting stent cell size using micro-CT: important data for bifurcation stent selectionEuroInterv.2008;4:391-396
How should I treat?
69
Stent migration as a late complication following carotid angioplasty and stentingEuroInterv.2008;4:397-404
Technical report
Volume 4 Number 3 has been released thanks to the support of the following partners:
- Abbott Vascular Devices
- Clearstream Technologies
- Cordis, a Johnson & Johnson company
- Hexacath
- Medtronic
- Terumo
- Zoll Medical Corporation


